Cavidi Webinar Q&A: Insights on BOLD Signal Amplification for ELISAs
This article provides a follow-up to a webinar hosted by BioTechniques in association with Cavidi, featuring Peter Stenlund, Principal Scientist at Cavidi AB. The session addressed technical questions regarding BOLD signal amplification technology for enhancing existing ELISA assays. Stenlund explained that while increased sensitivity lowers the Upper Limit of Quantification (ULOQ) due to earlier signal saturation, it allows for better characterization of baseline biological levels. Samples exceeding the ULOQ can be diluted for accurate quantification. The discussion also highlighted the preference for click chemistry over NHS-ester conjugation for antibody-oligo linking, citing superior stability and reproducibility of DBCO-modified oligos. Furthermore, the technology was compared to immuno-PCR, noting that BOLD avoids contamination risks and high-temperature cycling issues associated with PCR methods. The content serves as a technical resource for researchers utilizing ultra-sensitive immunoassay solutions in protein drug characterization and clinical biomarker detection.
Wire timeline
Cavidi Webinar Q&A: Insights on BOLD Signal Amplification for ELISAs
This article provides a follow-up to a webinar hosted by BioTechniques in association with Cavidi, featuring Peter Stenlund, Principal Scientist at Cavidi AB. The session addressed technical questions regarding BOLD signal amplification technology for enhancing existing ELISA assays. Stenlund explained that while increased sensitivity lowers the Upper Limit of Quantification (ULOQ) due to earlier signal saturation, it allows for better characterization of baseline biological levels. Samples exceeding the ULOQ can be diluted for accurate quantification. The discussion also highlighted the preference for click chemistry over NHS-ester conjugation for antibody-oligo linking, citing superior stability and reproducibility of DBCO-modified oligos. Furthermore, the technology was compared to immuno-PCR, noting that BOLD avoids contamination risks and high-temperature cycling issues associated with PCR methods. The content serves as a technical resource for researchers utilizing ultra-sensitive immunoassay solutions in protein drug characterization and clinical biomarker detection.
BioTechniques